IN2014DN00145A - - Google Patents

Download PDF

Info

Publication number
IN2014DN00145A
IN2014DN00145A IN145DEN2014A IN2014DN00145A IN 2014DN00145 A IN2014DN00145 A IN 2014DN00145A IN 145DEN2014 A IN145DEN2014 A IN 145DEN2014A IN 2014DN00145 A IN2014DN00145 A IN 2014DN00145A
Authority
IN
India
Prior art keywords
solid forms
amide
pharmaceutical compositions
present
relates
Prior art date
Application number
Other languages
English (en)
Inventor
Isabelle Sylvie Gallou
Cornelius Gauer
Frank Stowasser
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IN2014DN00145A publication Critical patent/IN2014DN00145A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IN145DEN2014 2011-06-21 2012-06-19 IN2014DN00145A (th)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161499222P 2011-06-21 2011-06-21
PCT/EP2012/061756 WO2012175522A1 (en) 2011-06-21 2012-06-19 Polymorphs of (s)-pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl}-amide

Publications (1)

Publication Number Publication Date
IN2014DN00145A true IN2014DN00145A (th) 2015-05-22

Family

ID=46319784

Family Applications (1)

Application Number Title Priority Date Filing Date
IN145DEN2014 IN2014DN00145A (th) 2011-06-21 2012-06-19

Country Status (11)

Country Link
US (1) US9006270B2 (th)
EP (1) EP2723733A1 (th)
JP (1) JP2014517049A (th)
KR (1) KR20140033432A (th)
CN (1) CN103619840B (th)
BR (1) BR112013032687A2 (th)
CA (1) CA2839621A1 (th)
IN (1) IN2014DN00145A (th)
MX (1) MX2013014887A (th)
RU (1) RU2014101626A (th)
WO (1) WO2012175522A1 (th)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3140959A1 (en) 2009-11-27 2011-06-03 Genzyme Corporation An amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase
MX2014011843A (es) * 2012-03-30 2014-12-10 Novartis Ag Compuestos para usarse en el tratamiento de neuroblastoma, sarcoma de ewing o rabdomiosarcoma.
CN105979947A (zh) * 2013-12-06 2016-09-28 诺华股份有限公司 α-同工型选择性磷脂酰肌醇3-激酶抑制剂的剂量方案
KR102598782B1 (ko) * 2014-10-03 2023-11-07 노파르티스 아게 알펠리십을 포함하는 제약 조성물
CA3137152A1 (en) 2019-04-18 2020-10-22 The Johns Hopkins University Substituted 2-amino-pyrazolyl-[1,2,4]triazolo[1,5a] pyridine derivatives and use thereof
CN112961090A (zh) * 2019-12-13 2021-06-15 武汉九州钰民医药科技有限公司 合成Alpelisib的关键中间体及其制备方法
CN111057051A (zh) * 2019-12-16 2020-04-24 武汉九州钰民医药科技有限公司 PI3K抑制剂Alpelisib的新合成方法
CN110964005A (zh) * 2019-12-16 2020-04-07 武汉九州钰民医药科技有限公司 一种Alpelisib的制备工艺
JP7649637B2 (ja) 2020-10-06 2025-03-21 エルジー ディスプレイ カンパニー リミテッド 伝送装置及び表示システム
AU2021362678A1 (en) 2020-10-13 2023-05-04 The Johns Hopkins University SUBSTITUTED 4-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)THIOPHENE-2-CARBOXAMIDE DERIVATIVES AND USE THEREOF
US20240216284A1 (en) * 2021-05-03 2024-07-04 Novartis Ag Alpelisib formulation
CN116925023B (zh) * 2023-07-18 2025-11-21 江苏桐孚高新材料有限公司 2-全氟烷基-4h-吡喃-4-酮衍生物的改进合成方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY29149A1 (es) * 2004-10-07 2006-05-31 Boehringer Ingelheim Int Tiazolil-dihidro-indazoles
JP2009535386A (ja) * 2006-05-03 2009-10-01 アストラゼネカ アクチボラグ チアゾール誘導体および抗腫瘍剤としてのその使用
UA104147C2 (uk) 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
AR082418A1 (es) * 2010-08-02 2012-12-05 Novartis Ag Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico

Also Published As

Publication number Publication date
KR20140033432A (ko) 2014-03-18
CN103619840B (zh) 2016-01-20
BR112013032687A2 (pt) 2016-08-30
AU2012274141B2 (en) 2015-12-24
US9006270B2 (en) 2015-04-14
US20140171470A1 (en) 2014-06-19
JP2014517049A (ja) 2014-07-17
EP2723733A1 (en) 2014-04-30
AU2012274141A1 (en) 2013-12-12
CN103619840A (zh) 2014-03-05
CA2839621A1 (en) 2012-12-27
WO2012175522A1 (en) 2012-12-27
MX2013014887A (es) 2014-02-17
RU2014101626A (ru) 2015-07-27

Similar Documents

Publication Publication Date Title
IN2014DN00145A (th)
NZ716487A (en) Process for the preparation of n-[5-(3,5-difluoro-benzyl)-1h-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide
ZA201201791B (en) Method for the preparation of 2,5-furandicarboxylic acid and esters thereof
ZA201201974B (en) Method for the preparation of 2,5-furandicarboxylic acid and for the prepartion of the dialkyl ester of 2,5-furandicarboxylic acid
MY163394A (en) Substituted aminobutyric derivates as neprilysin inhibitors
NZ704662A (en) Crystalline forms of the prolyl hydroxylase inhibitor [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid
TN2012000465A1 (en) Derivatives of 1-amino-2-cyclopropylethylboronic acid
EA020703B9 (ru) Пиразолохиназолины
SG10201805198TA (en) 18f - fluciclovine compositions in citrate buffers
MX2015004947A (es) Sistema cristalino multicomponente que comprende nilotinib y formadores de cocristal seleccionados.
PH12016500394A1 (en) Polymorphic form of pyrrole derivative and intermediate thereof
IN2015DN01151A (th)
PH12017500089B1 (en) Aldosterone synthase inhibitors
PH12014501195A1 (en) Novel 2h-indazoles as ep2, receptor antagonists
PT2429507T (pt) Composição farmacêutica isenta de fosfatos para o tratamento do glaucoma
MX2012008413A (es) Composicion novedosa de retigabina.
CA2894715C (en) Diazole amides
IN2013DN02555A (th)
MX339361B (es) Derivados de alternano.
SI2532651T1 (sl) Postopek sinteze in kristalinična oblika 4-(3-(cis-heksahidrociklopenta(c)pirol-2(1H)-il)propoksi) benzamid hidroklorida ter njegova prosta baza, pa tudi farmacevtski sestavki, ki ju vsebujejo
IN2013MN00811A (th)
PH12013500945A1 (en) Crystalline forms of an alkoxymidazol-1-ylmethyl-biphenyl carboxylic acid
JO2851B1 (en) 3-benzofuranil-indole-2-one-3-substituted acetamidopiprazine derivatives, preparations thereof and therapeutic use thereof.
MX351994B (es) Formas cristalinas de [(s)-1-carbamoil-2-(feniil-pirimidin-2-il-am ino)-etil]-amida del acido 2-(2-metilamino-pirimidin-4-il)-1h-indo l-5-carboxilico.
GB201204081D0 (en) An improved process for the synthesis of alkyl/aralkyl (2S)-2-(tert-butoxycarbonyl)-amino-2-[-8-azabicyclo[3.2.1]oct-3-yl]-exo-ace tate and analogs thereof